pirfenidone has been researched along with Connective Tissue Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behr, J; Günther, A; Kreuter, M; Neuser, P; Prasse, A; Rabe, K; Schade-Brittinger, C; Wagner, J | 1 |
| Adegunsoye, A; Strek, ME | 1 |
1 review(s) available for pirfenidone and Connective Tissue Diseases
| Article | Year |
|---|---|
Therapeutic Approach to Adult Fibrotic Lung Diseases.
Topics: Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Diseases; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Prognosis; Pyridones | 2016 |
1 trial(s) available for pirfenidone and Connective Tissue Diseases
| Article | Year |
|---|---|
Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Diseases; Disease Progression; Double-Blind Method; Female; Humans; Lung; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Research Design; Treatment Outcome; Vital Capacity; Young Adult | 2017 |